SpaceX investor backs Toronto AI upstart's journey into the 'dark region' of genetic diseases

Brendan Frey set out, when he began the project to pick out a lead program for Deep Genomics, to prove that the artificial intelligence systems his lab has designed can identify new drug targets and find a winning candidate much faster than traditional methods.